[Immunoscintigraphy with radionuclide-labeled monoclonal antibodies for tumor diagnosis and in benign diseases].
Immunoscintigraphy using radiolabeled (technetium-99m, indium-111, iodine-131) monoclonal antibodies is successfully (sensitivity over 80%, specificity over 90%) applied since some years in the clinic for the detection of CEA- and or CA 19-9-producing colorectal and CA 125-positive ovarian carcinoma recurrences and just recently for the diagnosis of benign diseases (myocardial infarction/transplant rejection/thrombosis/abscess localization.
Baum
R P
RP
Zentrum der Radiologie, Universität, Frankfurt.
Hertel
A
A
Hör
G
G
D000038:Abscess / Q000000981:diagnostic imaging*; D000911:Antibodies, Monoclonal; D002277:Carcinoma / Q000000981:diagnostic imaging*; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal
Immunszintigraphie mit radionuklidmarkierten monoklonalen Antikörpern zur Tumordiagnostik und bei benignen Erkrankungen.